Zonisamide (Epilepsy)

Table   Graphic  
individual studies
OutcomeTE95% CIn casesn exposedkPub. bias Congenital malformations All congenital malformations (majors, minors, majors and minors, or unspecified) Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2012 Tomson (Zonisamide), 2018 Meador (Zonisamide) (Controls unexposed, sick), 2020 31.01[0.19; 5.31]81112not evaluable Major congenital malformations Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2012 Tomson (Zonisamide), 2018 Meador (Zonisamide) (Controls unexposed, sick), 2020 31.01[0.19; 5.31]81112not evaluable Growth parameters and prematurity Low birth weight (< 2500g) Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2014 12.17[0.91; 5.14]2698not evaluable Preterm (< 37 weeks) Hernández-Díaz (Zonisamide) (Controls unexposed, disease free), 2014 11.81[0.85; 3.87]3798not evaluable Small for gestational age (weight) Hernández-Díaz (Zonisamide), 2017 11.90[1.20; 3.00]-125not evaluable Intrauterine deaths Intrauterine deaths (as a whole or unspecified) Meador (Zonisamide) (Controls unexposed, sick), 2020 11.16[0.02; 62.85]-13not evaluable Neuro-developmental disorders Language disorders/delay Meador (Zonisamide) (Controls unexposed, disease free), 2021 10.33[0.10; 1.06]-11not evaluable0.0100.01.0

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons